Miller Cari L, Kerr Thomas, Frankish James C, Spittal Patricia M, Li Kathy, Schechter Martin T, Wood Evan
British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada.
Subst Use Misuse. 2006;41(2):199-210. doi: 10.1080/10826080500391795.
Several studies have highlighted risk factors that cause HIV vulnerability among injection drug users (IDUs); these studies in turn have prompted public health officials to take action to minimize these risks. We sought to evaluate the potential association between binge drug use and HIV seroconversion and, subsequently, risk factors associated with binge drug use among a cohort of IDUs. To do this, we performed analyses of (1) associations with HIV seroconversion and (2) associations with binge drug use among participants enrolled in the Vancouver Injection Drug Users Study (VIDUS), a prospective cohort of IDU. Because serial measures for each individual were available, we undertook a time-updated Cox regression analysis to detect associations with HIV incidence and variables potentially associated with binge drug use were evaluated by using generalized estimating equations (GEE). Overall, 1548 IDU were enrolled into the VIDUS cohort between May 1996 and May 2003. There were 1013 individuals who were HIV seronegative at enrollment and had at least one follow-up visit; 125 (12%) became HIV positive during the study period for a cumulative incidence rate of 14% at 64 months after enrollment. In the final multivariate model, binge drug use [Adjusted Hazards Ratio: 1.61 (CI: 1.12, 2.31)] was independently associated with HIV seroconversion. In subanalyses, when we evaluated associations with binge drug use in GEE analyses, borrowing [Odds Ratio (OR): 153 (CI: 1.33-1.76)] and lending [OR: 1.73 (CI: 1.50-1.98)] syringes, sex trade work [OR: 1.14 (CI: 1.01-1.29)], frequent cocaine [OR: 2.34 (CI: 2.11-2.60)] and heroin [OR: 1.29 (CI: 1.17-1.43)] injection were independently associated with binge drug use and methadone [OR: 0.80 (CI: 0.71-0.89)] was protective against binge drug use. Our study identified an independent association between binge drug use and HIV incidence and demonstrated several high-risk drug practices associated with bingeing. Given the unaddressed public health risks associated with bingeing, a public health response protocol must be developed to minimize the personal and public health risks associated with the binge use of drugs.
多项研究强调了导致注射吸毒者(IDU)感染艾滋病毒易感性的风险因素;这些研究进而促使公共卫生官员采取行动,将这些风险降至最低。我们试图评估狂饮毒品与艾滋病毒血清转化之间的潜在关联,以及随后在一组注射吸毒者中与狂饮毒品相关的风险因素。为此,我们对参与温哥华注射吸毒者研究(VIDUS)的参与者进行了两项分析:(1)与艾滋病毒血清转化的关联;(2)与狂饮毒品的关联。VIDUS是一个注射吸毒者的前瞻性队列。由于可以获得每个个体的系列测量数据,我们进行了时间更新的Cox回归分析,以检测与艾滋病毒发病率的关联,并使用广义估计方程(GEE)评估可能与狂饮毒品相关的变量。总体而言,1996年5月至2003年5月期间,有1548名注射吸毒者被纳入VIDUS队列。有1013名个体在入组时艾滋病毒血清学阴性且至少有一次随访;125人(12%)在研究期间艾滋病毒呈阳性,入组后64个月的累积发病率为14%。在最终的多变量模型中,狂饮毒品[调整后风险比:1.61(CI:1.12,2.31)]与艾滋病毒血清转化独立相关。在亚分析中,当我们在GEE分析中评估与狂饮毒品的关联时,借用[优势比(OR):1.53(CI:1.33 - 1.76)]和出借[OR:1.73(CI:1.50 - 1.98)]注射器、性交易工作[OR:1.14(CI:1.01 - 1.29)]、频繁注射可卡因[OR:2.34(CI:2.11 - 2.60)]和海洛因[OR:1.29(CI:1.17 - 1.43)]与狂饮毒品独立相关,而美沙酮[OR:0.80(CI:0.71 - 0.89)]对狂饮毒品有预防作用。我们的研究确定了狂饮毒品与艾滋病毒发病率之间的独立关联,并证明了几种与狂饮相关的高风险吸毒行为。鉴于与狂饮相关的公共卫生风险尚未得到解决,必须制定一项公共卫生应对方案,以尽量减少与狂饮毒品相关的个人和公共卫生风险。